

Breath Actuated delivery for true on-demand therapy



AeroEclipse II

BAN* Nebulizer

- 7 days, disposable
- Single-patient use
- Ideal for short-term acute care



AeroEclipse XL


BAN* Nebulizer

- 6 months, reusable
- Single- or multi-patient[‡] use
- Ideal for the home environment

‡ If cleared in market

More drug delivered to the lungs

Percentage of Deposited Dose (%)¹



In vivo deposition patterns demonstrate that the **AEROECLIPSE* II BAN*** Nebulizer delivers more aerosolized medication to the lungs (75.0%) compared to a conventional small volume jet nebulizer (46.8%). Less aerosolized medication ends up in the stomach with the **BAN*** compared to a conventional SVN.¹

¹ Sample scintigraphy image. Eight healthy subjects received albuterol (2.5 mg/3 mL) admixed with 2 mCi of Tc-DTPA (Technetium-99m bound to diethylenetriaminepentaacetic acid). *Comparative Scintigraphic Assessment of Deposition of Radiolabeled Albuterol Delivered from a Breath Actuated Nebulizer and a Small Volume Jet Nebulizer to Healthy Subjects.* Corcoran T, et al. *Respiratory Care* 2019;64(10):3235-398.



aeroeclipse.com

AeroEclipse*

BAN* Nebulizers

Clinical Reference Sheet

	MEDICATION	SUMMARY
Antibiotic	Colistimethate Sodium	<i>In vitro</i> study concludes conservation of Colomycin [†] medication and avoidance of environmental losses from fugitive emissions with the AEROECLIPSE[®] XL BAN[®] Nebulizer system was evident by the increased fine particle mass, compared with the PARI LC PLUS [†] BEN system. Inhaled Antibiotic Delivery By Pneumatic Nebulization: Case Study Comparing Breath Actuated With Breath Enhanced Nebulizers For Colistimethate Sodium. JA Suggett, <i>et al.</i> Respiratory Drug Delivery 2014;3:581-584.
	Tobramycin	<i>In vitro</i> study finds the AEROECLIPSE[®] XL BAN[®] Nebulizer delivers an appreciably higher total mass of TOBI [†] than the PARI LC PLUS [†] breath enhanced nebulizer. Delivery Of Tobramycin Via Pneumatic Nebulizer: A Laboratory Study Comparing Breath-Actuated And Breath-Enhanced Devices. JA Suggett, <i>et al.</i> American Journal of Respiratory and Critical Care Medicine 2014;189: A2847.
Anticholinergic	Ipratropium Bromide	<i>In vitro</i> study concludes use of the AEROECLIPSE[®] XL BAN[®] Nebulizer provides assurance of dose consistency independent of the patient's duty cycle. A Laboratory Study Comparing Breath Actuated And Breath Enhanced Nebulizer Devices At Various Duty Cycles Associated With COPD. JA Suggett, <i>et al.</i> American Journal of Respiratory and Critical Care Medicine 2014;189: A3035.
Bronchodilator	Albuterol	<i>In vitro</i> study concludes higher and more consistent dose delivery was achieved by the AEROECLIPSE[®] II BAN[®] Nebulizer across the range of inhalation:exhalation ratios tested compared to other types of nebulizers. Dose Assurance With Nebulizer Therapy – A Laboratory Investigation Into The Medication Delivery Performance Of A Range Of Different Nebulizers At Different Inspiratory/Expiratory Ratios. M Nagel, <i>et al.</i> American Journal of Respiratory and Critical Care Medicine 2021;203:A4672.
		<i>In vitro</i> study reports the AEROECLIPSE[®] II BAN[®] Nebulizer has substantially reduced environmental emissions compared to alternative constant output and breath enhanced nebulizers. A Laboratory-Based Examination Of The Potential For Fugitive Emission Of Aerosols To The Local Environment From A Range Of Commercially Available Nebulizer Systems. M. Nagel, <i>et al.</i> Respiratory Drug Delivery 2021. 2021:1;287-292.
Corticosteroid	Budesonide	<i>In vitro</i> study reports the AEROECLIPSE[®] XL BAN[®] Nebulizer achieves a more consistent dose delivery across the range of inhalation:exhalation ratios tested compared to 3 breath enhanced nebulizers (PARI LC PLUS [†] , PARI LC Sprint [†] , Philips Respironics [†] SideStream [†] Plus). Delivery Of Inhaled Medication Is Maintained By A Breath Actuated Nebulizer When Used By Patients With Differing Inhalation / Exhalation Ratios: A Laboratory Study Using Budesonide Suspension For Nebulization. J Suggett, <i>et al.</i> Respiratory Drug Delivery 2014;3:573-576.
Mucolytic	Dornase Alfa	<i>In vitro</i> study reports the AEROECLIPSE[®] XL BAN[®] Nebulizer exhibited a slightly higher delivery of Pulmozyme [†] compared to the PARI LC PLUS [†] breath enhanced nebulizer. Delivery Of Dornase Alfa Via Breath-Actuated Nebulizer: <i>In Vitro</i> Measures Of Performance. J Suggett, <i>et al.</i> European Respiratory Journal 2013;42:P1186.
	Hypertonic Saline (7%)	<i>In vitro</i> study concludes use of the AEROECLIPSE[®] XL BAN[®] Nebulizer with or without the concurrent use of the Aerobika[®] OPEP device, appears to be an effective method of delivering hypertonic saline. Use Of An Oscillating Positive Expiratory Pressure (OPEP) Device With A Breath Actuated Nebulizer For The Delivery Of Hypertonic Saline. DP Coppola, <i>et al.</i> Pediatric Pulmonology 2016;S45(51):S194-S485.

For a comprehensive overview of published studies refer to the **AEROECLIPSE[®] BAN[®]** Nebulizer Study Summary.

